Ryaltris is a new nasal spray (formerly GSP301) that is being investigated by Glenmark Pharmaceuticals for the treatment of seasonal allergic rhinitis in patients 12 years and older. Ryaltris consists of 2 drugs, the first one is olopatadine hydrochloride, a nasal antihistamine, which is the medication used in Patanase nasal spray. The second medication […]
Tree Nut Allergy: Is it the new Peanut Allergy?
Tree nut allergy is usually lifelong and together with peanut allergy are the most common cause of food induced anaphylaxis. There is not as much data compared to peanut allergy. Children with peanut allergy are thought to be at increased risk of tree nut allergies, with around 30% of pediatric patients presenting with peanut allergy […]
Adult Eczema: A Clinical Review
Approximately 1 in 4 adults report the onset of adult eczema and the rest its onset is from childhood. Eczema is an ill-defined skin lesions and it includes patches, papules, and plaques with different degrees of redness and swelling. It can affect any skin site but they most classically affect the creases of the elbows […]
Fezakinumab an IL-22 antagonist for Eczema
IL-22 upregulation characterizes atopic dermatitis lesions. However, blocking IL-22 has not been defined in human subjects. A recent study sought to evaluate the cellular and molecular effects of fezakinumab (anti-IL-22) versus placebo taken from biopsy specimens. Atopic dermatitis is the most common chronic inflammatory skin disease with increasing prevalence. IL-4 and IL-13 are the 2 […]
Tralokinumab for Atopic Dermatitis
Tralokinumab is a fully human monclonal antibody that potently and specifically neutralizes IL-13. IL-13 has an important role in atopic dermatitis pathogenesis. Atopic dermatitis (eczema) is a chronic inflammatory skin disease. It can affect sleep, psychosocial activities and health related quality of life. The symptoms of many patients are not controlled with current treatment regimens. […]
Nucala vs. Fasenra vs. Cinqair; A Comparison Study
Three anti-IL-5 pathway directed therapies are approved for use in patients with severe eosinophilic asthma, however no head to head comparison data are available. Nucala (mepolizumab) and Cinqair (reslizumab) target IL-5 and Fasenra (benralizumab) binds to the IL-5 receptor. All 3 therapies have demonstrated statistically significant reductions in exacerbation rates. Additionally, Nucala and Fasenra reduced […]
Other Conditions in Eosinophilic Esophagitis
Eosinophilic esophagitis is a chronic immune-mediated inflammatory condition characterized by eosinophils infiltrating the esophagus occurring in 1 in 2,000 individuals. Since the 1990’s its incidence has been increasing and it is the most common cause of chronic swallowing problems in the developed world. It is characterized by a food allergy-driven process, with a high rate […]
New Eczema Medications in the Pipeline
In the past year or so, new eczema medications have been released that have been highly beneficial for patients. We have seen Eucrisa (crisaborole) New Eczema Medication gets FDA Approval, this is a topical medication which is an inhibitor of phosphodiesterase 4-depndent cyclic adenosine monophosphate degradation. It was approved in 2016 for mild to moderate atopic […]
Bethenny Frankel Suffers Allergic Reaction
Bethenny Frankel from the hit reality show, Real Housewives of New York, suffered what was reported an anaphylactic episode. In a previous season of her show, she had a reaction after eating fish, she has stated that she has a rare fish allergy. This most recent episode occurred after eating soup which contained fish in […]
AR201 a treatment for Egg Allergy by Aimmune
AR201 is currently being developed by Aimmune Therapeutics for the treatment of egg allergy. If Aimmune sounds familiar to you, it is because they will be releasing the first treatment of peanut allergy by the end of 2019, AR101. AR101 a Potential Peanut Allergy Cure Aimmune expects to initiate a Phase 2 clinical trial of […]
- 1
- 2
- 3
- …
- 28
- Next Page »